Blog - Page 937 of 5753 - QualityStocks

WednesdaySep 21, 2022 10:30 am

Correlate Infrastructure Partners Inc. (CIPI) Expands Renewable Energy Industry Reach by Entering Northeast Market

Correlate recently announced its letter of intent to acquire Vermont-based Aegis Renewable Energy and plans to use its deep regulatory knowledge, project fulfillment and operations and maintenance capabilities to deliver on and expand its project backlog in the region Correlate is at the forefront of creating industry-leading energy solutions and financing platforms for commercial and industrial sectors The portfolio for energy optimization is a $290 billion market, driving deep financial savings and energy efficiency across the commercial sector Correlate Infrastructure Partners (OTCQB: CIPI), a technology-enabled energy optimization and clean energy solutions provider for all of North America, is expanding its…

WednesdaySep 21, 2022 9:45 am

GeoSolar Technologies Inc. Positioned to Benefit from Biden Administration Plans to Expand Geothermal Technology

U.S. Department of Energy recently announced Biden administration plans to reduce geothermal system costs by 90% to $45 per megawatt hour by 2035 GeoSolar’s SmartGreen(R) residential and commercial energy systems leverage solar and geothermal energy to dramatically lower or eliminate utility bills Additional SmartGreen(R) system customizations include tightening building envelope, insulation upgrades, LED lighting replacement, EV charging infrastructure The U.S. Department of Energy (“DOE”) recently announced that the Biden administration plans to reduce geothermal system costs by 90% to $45 per megawatt hour by 2035 (https://nnw.fm/JJHUW). Increased awareness and mainstream adoption of the technology will likely benefit Colorado-based GeoSolar Technologies…

WednesdaySep 21, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Provide Bioavailable Oral Treatment for Hypertension, Mitigate Effects of High Blood Pressure

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2) Oral…

TuesdaySep 20, 2022 3:19 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Releases New Video Exploring Its Technologies, Progress of AIMIGo(TM) Device

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. The company today announced that, in conjunction with its upcoming virtual roadshow webinar taking place at 4:30 p.m. ET on Tuesday, Sept. 20, 2022, it has released a new video that takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology. “This new video provides a compelling overview and explanation of our technologies and highlights our continued progress toward making the AIMIGo device available for remote heart attack detection,” said Branislav Vajdic,…

TuesdaySep 20, 2022 2:26 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Hypertension Drug Market with Proprietary Drug-Delivery Method

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is focused on establishing a stronghold in the $28 billion hypertension drug market. The company’s exclusive therapeutic, DehydraTECH-CBD, has shown exciting potential as an alternative to traditional cannabidiol (“CBD”) dosing methods; the proprietary treatment may offer improved and more rapid absorption of drugs into the bloodstream and brain. According to the announcement, only one FDA-approved CBD drug is currently available on the market; that drug is for pediatric epilepsy. Lexaria is working to offer the second-ever, FDA-approved CBD therapeutic, designed to treat hypertension. The market for the treatment is tremendous,…

TuesdaySep 20, 2022 1:41 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs from lab to clinic and have enabled the company to discover potential new drug formulations and delivery methods as well as create clinical protocols for psychedelic compounds and support clinical-stage development of CYBN’s proprietary CYB003…

TuesdaySep 20, 2022 1:30 pm

Freight Technologies Inc. (NASDAQ: FRGT) Using Technology to Help Customers Overcome Challenges of Cross-Border Logistics, Greatly Improving Efficiency

Freight Technologies is a technology company that develops solutions aimed at optimizing and automating the supply chain process The company’s solutions include Fr8App Platform, Fr8FMS, cloud-based Fr8TMS, Fr8Radar, Fr8Data, and Fr8Fleet Early this year, Freight Technologies unveiled Fr8Fleet, a technology solution for committed capacity planning, and announced it had secured its first contract for this product with Kimberly Clark de Mexico (“KCM”) The company recently reported an expanded relationship with KCM following an agreement to include the Fr8App platform for cross-border logistics for shipments from Mexico to the U.S. An insights report by multinational KPMG, entitled “The challenges of cross-border…

TuesdaySep 20, 2022 12:45 pm

Flora Growth Corp. (NASDAQ: FLGC) Agreement with Colombian Tribe Strengthens Cannabis Production Supply Chain

Flora Growth is a global cannabis brand-builder focused on the cultivation of product at a central Colombian facility and marketing through a design-led international supply chain Flora recently announced an agreement with Colombia’s Misak tribe for cooperative processing and distribution of cannabis, drawing on the tribe’s licensing advantage to accelerate the pair’s marketing capacity Flora is headquartered in Canada, but its strength lies in its Colombian-based cultivation operations centered in Colombia, one of the largest licensed outdoor operations in the world In recent years, Colombia’s government has been working to create a legalization framework for cannabis cultivation, processing and exportation…

TuesdaySep 20, 2022 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective therapeutics. The company is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. Late last month, the first two trial participants…

TuesdaySep 20, 2022 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organization QSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populations Company creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences (OTCQB: QSAM) is becoming increasingly important. QSAM Biosciences is a clinical-stage biotechnology company focused on developing and bringing to market targeted therapeutic radiopharmaceuticals and advancing the fight against cancer, including the underserved pediatric…

Site Search

Company Search